Program
SM17
Also written as “SM17 for injection”.
Its studies are mostly in Dermatitis, Atopic · Asthma, led by SinoMab BioScience.
Furthest: phase 1, since Mar 31, 20223 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SinoMab BioScience | 30 open or running | phase 1since Mar 31, 2022 | Mar 31, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 31, 2022First study: phase 1 study in AsthmaFirst studyNCT05332834 · 77 enrolled · United States
- Jul 21, 2025Phase 1 study in Dermatitis, AtopicNCT07103369 · 64 enrolled · China
- Mar 3, 2026Phase 1 study in Dermatitis, AtopicNCT07466940 · 30 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07466940Dermatitis, Atopic · China | 1 | Completed | Feb 3, 2026 | 30 |
| NCT07103369Dermatitis, Atopic · China | 1 | Completed | Mar 24, 2025 | 64 |
| NCT05332834Asthma · United States | 1 | Completed | Sep 26, 2023 | 77 |
How it is read
Names in the registry
- “SM17”, 2 entries
- “SM17 for injection”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.